Do analysts rate CALC or ADXS?

CalciMedica currently has a consensus target price of $10.00, indicating a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CALC or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% Ayala Pharmaceuticals N/A N/A N/A

Do analysts recommend CALC or MIRA?

CalciMedica currently has a consensus price target of $10.00, indicating a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts plainly believe CalciMedica is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, CALC or MIRA?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.36 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is CALC or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% MIRA Pharmaceuticals N/A -106.95% -104.18%

Do analysts prefer CALC or UG?

CalciMedica presently has a consensus target price of $10.00, suggesting a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher possible upside, research analysts plainly believe CalciMedica is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate CALC or PYRGF?

CalciMedica presently has a consensus target price of $10.00, indicating a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to CALC or PYRGF?

In the previous week, PyroGenesis Canada had 2 more articles in the media than CalciMedica. MarketBeat recorded 3 mentions for PyroGenesis Canada and 1 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GLMD or CALC?

CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has preferable earnings & valuation, GLMD or CALC?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$7.28 N/A CalciMedica N/A N/A -$29.56M -$1.36 N/A

Is GLMD or CALC more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% CalciMedica N/A -863.40% -155.24%

Does the media refer more to GLMD or CALC?

In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for Galmed Pharmaceuticals and 1 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.00 beat Galmed Pharmaceuticals' score of -0.14 indicating that CalciMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CalciMedica (CALC) Competitors

$0.56 -0.02 (-2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$0.56 0.00 (-0.07%)

As of 04:10 PM Eastern

Compare

CALC vs. ADXS, MIRA, UG, PYRGF, and GLMD

Should you buy CalciMedica stock or one of its competitors? CalciMedica's main competitors and comparable companies include Ayala Pharmaceuticals (ADXS), MIRA Pharmaceuticals (MIRA), United-Guardian (UG), PyroGenesis Canada (PYRGF), and Galmed Pharmaceuticals (GLMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CalciMedica compare to Ayala Pharmaceuticals?

CalciMedica (NASDAQ:CALC) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Ayala Pharmaceuticals' return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
Ayala Pharmaceuticals	N/A	N/A	N/A

CalciMedica has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CalciMedica has higher earnings, but lower revenue than Ayala Pharmaceuticals. CalciMedica is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.36	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

In the previous week, CalciMedica had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for CalciMedica and 0 mentions for Ayala Pharmaceuticals. CalciMedica's average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
Ayala Pharmaceuticals	Neutral

CalciMedica currently has a consensus target price of $10.00, indicating a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CalciMedica beats Ayala Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does CalciMedica compare to MIRA Pharmaceuticals?

CalciMedica (NASDAQ:CALC) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, CalciMedica had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for CalciMedica and 0 mentions for MIRA Pharmaceuticals. CalciMedica's average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
MIRA Pharmaceuticals	Neutral

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.36	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

MIRA Pharmaceuticals' return on equity of -106.95% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

CalciMedica has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 28.3% of CalciMedica shares are owned by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CalciMedica currently has a consensus price target of $10.00, indicating a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts plainly believe CalciMedica is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CalciMedica and MIRA Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does CalciMedica compare to United-Guardian?

CalciMedica (NASDAQ:CALC) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, CalciMedica had 1 more articles in the media than United-Guardian. MarketBeat recorded 1 mentions for CalciMedica and 0 mentions for United-Guardian. CalciMedica's average media sentiment score of 0.00 equaled United-Guardian'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
United-Guardian	Neutral

CalciMedica has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, United-Guardian has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

United-Guardian has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.36	N/A
United-Guardian	$11.21M	2.93	$2.11M	$0.54	13.22

23.2% of United-Guardian shares are owned by institutional investors. 28.3% of CalciMedica shares are owned by insiders. Comparatively, 29.0% of United-Guardian shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CalciMedica presently has a consensus target price of $10.00, suggesting a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher possible upside, research analysts plainly believe CalciMedica is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

United-Guardian has a net margin of 22.01% compared to CalciMedica's net margin of 0.00%. United-Guardian's return on equity of 22.24% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
United-Guardian	22.01%	22.24%	19.12%

Summary

United-Guardian beats CalciMedica on 10 of the 14 factors compared between the two stocks.

How does CalciMedica compare to PyroGenesis Canada?

CalciMedica (NASDAQ:CALC) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

CalciMedica presently has a consensus target price of $10.00, indicating a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, PyroGenesis Canada had 2 more articles in the media than CalciMedica. MarketBeat recorded 3 mentions for PyroGenesis Canada and 1 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
PyroGenesis Canada	-115.14%	N/A	-60.81%

CalciMedica has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than CalciMedica. PyroGenesis Canada is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.36	N/A
PyroGenesis Canada	$9.14M	3.74	-$21.12M	-$0.04	N/A

0.0% of PyroGenesis Canada shares are held by institutional investors. 28.3% of CalciMedica shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

PyroGenesis Canada beats CalciMedica on 8 of the 14 factors compared between the two stocks.

How does CalciMedica compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Galmed Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for Galmed Pharmaceuticals and 1 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.00 beat Galmed Pharmaceuticals' score of -0.14 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 28.3% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -35.32% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
CalciMedica	N/A	-863.40%	-155.24%

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$7.28	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.36	N/A

CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,697.27%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

CalciMedica beats Galmed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALC vs. The Competition

Export

Metric	CalciMedica	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.00M	$12.42B	$7.29B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	-0.41	780.42	271.39	24.10
Price / Sales	N/A	789.54	604.58	77.05
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	-1.21	10.42	11.18	6.40
Net Income	-$29.56M	$2.79B	$3.46B	$348.28M
7 Day Performance	-16.02%	2.25%	1.98%	0.92%
1 Month Performance	-26.78%	4.72%	7.32%	5.10%
1 Year Performance	-79.99%	7.07%	24.76%	16.16%

CalciMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALC CalciMedica	3.5981 of 5 stars	$0.56 -2.9%	$10.00 +1,697.3%	-79.4%	$19.00M	N/A	N/A	30	Analyst Upgrade
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
MIRA MIRA Pharmaceuticals	1.0089 of 5 stars	$0.78 +2.0%	N/A	-46.6%	$32.78M	N/A	N/A	2	Gap Up
UG United-Guardian	1.8173 of 5 stars	$7.05 -0.3%	N/A	-13.2%	$32.36M	$10.55M	13.06	20
PYRGF PyroGenesis Canada	N/A	$0.14 -4.6%	N/A	-36.0%	$32.21M	$9.14M	N/A	90	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CalciMedica (CALC) Competitors

CALC vs. ADXS, MIRA, UG, PYRGF, and GLMD

How does CalciMedica compare to Ayala Pharmaceuticals?

Summary

How does CalciMedica compare to MIRA Pharmaceuticals?

Summary

How does CalciMedica compare to United-Guardian?

Summary

How does CalciMedica compare to PyroGenesis Canada?

Summary

How does CalciMedica compare to Galmed Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CalciMedica (CALC) Competitors

CALC vs. ADXS, MIRA, UG, PYRGF, and GLMD

How does CalciMedica compare to Ayala Pharmaceuticals?

Is CALC or ADXS more profitable?

Which has more risk & volatility, CALC or ADXS?

Do insiders & institutionals believe in CALC or ADXS?

Which has stronger valuation and earnings, CALC or ADXS?

Does the media prefer CALC or ADXS?

Do analysts rate CALC or ADXS?

Summary

How does CalciMedica compare to MIRA Pharmaceuticals?

Does the media favor CALC or MIRA?

Which has stronger earnings & valuation, CALC or MIRA?

Is CALC or MIRA more profitable?

Which has more risk & volatility, CALC or MIRA?

Do institutionals and insiders have more ownership in CALC or MIRA?

Do analysts recommend CALC or MIRA?

Summary

How does CalciMedica compare to United-Guardian?

Does the media prefer CALC or UG?

Which has more risk and volatility, CALC or UG?

Which has stronger valuation & earnings, CALC or UG?

Do insiders & institutionals hold more shares of CALC or UG?

Do analysts prefer CALC or UG?

Is CALC or UG more profitable?

Summary

How does CalciMedica compare to PyroGenesis Canada?

Do analysts rate CALC or PYRGF?

Does the media refer more to CALC or PYRGF?

Is CALC or PYRGF more profitable?

Which has more volatility & risk, CALC or PYRGF?

Which has better valuation and earnings, CALC or PYRGF?

Do insiders & institutionals believe in CALC or PYRGF?

Summary

How does CalciMedica compare to Galmed Pharmaceuticals?

Which has more risk and volatility, GLMD or CALC?

Does the media refer more to GLMD or CALC?

Do insiders & institutionals hold more shares of GLMD or CALC?

Is GLMD or CALC more profitable?

Which has preferable earnings & valuation, GLMD or CALC?

Do analysts rate GLMD or CALC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools